RESUMEN
There is currently a paucity of data on salvage intracerebrospinal fluid (intra-CSF) chemotherapy in leptomeningeal metastases (LM). This report is a single-institution experience with salvage treatment in patients with breast cancer (BC) and LM. This retrospective cohort describes 24 consecutive patients with BC selected for a second-line of treatment for LM. The first line of LM treatment consisted of intra-CSF liposomal cytarabine in all patients combined with systemic therapy in 18 cases and radiotherapy in four cases. Second-line (salvage) treatment utilized intra-CSF thiotepa in all and systemic chemotherapy in nine patients. No patient received CNS-directed radiotherapy. The median Eastern Cooperative Oncology Group performance status at initiation of intra-CSF thiotepa treatment was 3 (range 1-4). The median progression-free survival and median survival following intra-CSF thiotepa was 3.1 months (range 3 days-2 years) and 4.0 months (range 6 days-2.5 years), respectively. The median overall survival from LM diagnosis was 9.5 months (range 1.3 months-2.7 years). No grade 3 or higher toxicity was observed. Recognizing the limits of a retrospective study, intra-CSF thiotepa has an acceptable toxicity profile and appears to be a reasonable option for selected BC patients.
Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias Meníngeas , Terapia Recuperativa , Tiotepa/uso terapéutico , Adulto , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/líquido cefalorraquídeo , Neoplasias de la Mama/líquido cefalorraquídeo , Neoplasias de la Mama/patología , Supervivencia sin Enfermedad , Femenino , Humanos , Neoplasias Meníngeas/líquido cefalorraquídeo , Neoplasias Meníngeas/tratamiento farmacológico , Neoplasias Meníngeas/secundario , Persona de Mediana Edad , Estudios Retrospectivos , Punción Espinal , Tiotepa/administración & dosificación , Tiotepa/líquido cefalorraquídeoRESUMEN
Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane. Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with leptomeningeal carcinomatosis. Diagnosis is based on compatible symptoms and signs, cytological evidence of malignancy in the cerebrospinal fluid, and neuroimaging studies. Treatment is largely palliative (median survival 2-4 months). Patients with lympomatous or leukaemic meningitis, chemosensitive tumours such as breast cancer, low tumour burden, minimal neurological deficits, good performance status and controllable systemic disease survive longer with occasional long-term responses. Available treatment options include focal radiation therapy to CNS sites of bulky, symptomatic or obstructive meningeal deposits, intrathecal cytotoxic therapy and systemic chemotherapy. No evidence of superiority of intrathecal treatment compared with best palliative care (including radiation therapy and systemic treatment) is available from clinical trials. Novel treatment approaches include intrathecal liposomal Ara-C, the development of new cytotoxic compounds, signal transduction inhibitors and monoclonal antibodies for intrathecal or systemic use. Until data from multi-centre randomised trials are available, rationalisation of therapy should be done by stratifying patients to prognostic groups. High-risk patients will only survive for a few weeks and are better managed with supportive measures, whereas low-risk patients justify vigorous cerebrospinal fluid-directed treatment combined with radiation therapy and systemic chemotherapy.
Asunto(s)
Quistes Aracnoideos/tratamiento farmacológico , Carcinoma/tratamiento farmacológico , Neoplasias Meníngeas/tratamiento farmacológico , Adenocarcinoma/patología , Algoritmos , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/líquido cefalorraquídeo , Antimetabolitos Antineoplásicos/uso terapéutico , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/líquido cefalorraquídeo , Antineoplásicos Alquilantes/uso terapéutico , Quistes Aracnoideos/etiología , Quistes Aracnoideos/radioterapia , Carcinoma/radioterapia , Carcinoma/secundario , Terapia Combinada , Irradiación Craneana , Citarabina/administración & dosificación , Citarabina/líquido cefalorraquídeo , Citarabina/uso terapéutico , Preparaciones de Acción Retardada , Inhibidores Enzimáticos/uso terapéutico , Humanos , Inyecciones Intravenosas , Inyecciones Espinales , Leucemia/patología , Linfoma/patología , Neoplasias Meníngeas/radioterapia , Neoplasias Meníngeas/secundario , Metotrexato/administración & dosificación , Metotrexato/líquido cefalorraquídeo , Metotrexato/uso terapéutico , Cuidados Paliativos , Ensayos Clínicos Controlados Aleatorios como Asunto , Tiotepa/administración & dosificación , Tiotepa/líquido cefalorraquídeo , Tiotepa/uso terapéutico , Inhibidores de Topoisomerasa I , Topotecan/uso terapéuticoRESUMEN
After treating a child suffering from disseminated primitive neuroectodermal tumor and hydrocephalus with bilateral ventriculostomies, we administered intravenous high dose thiotepa followed by a single subcutaneous dose of GM-CSF 24 hours later. The appearance and clearance of GM-CSF were measured from both ventricles, one of which was surrounded by tumor. Peak levels of GM-CSF were recorded simultaneously in both ventricles 11 hours after injection. Complete clearance from injection required 15 hours and 31 hours for the tumor-free right ventricle and the tumor-involved left ventricular wall, respectively. Tumor response was ephemeral and limited to ventricular fluid WBC, protein and LDH decreases. Microglia were detected; however, there was no evidence of anti-tumor activity in biopsied tumor tissue. Tumored regions of the brain may have perturbation of GM-CSF distribution and clearance which may contribute to the lack of microglial activity.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacocinética , Neoplasias Encefálicas/tratamiento farmacológico , Niño , Factor Estimulante de Colonias de Granulocitos y Macrófagos/líquido cefalorraquídeo , Humanos , Hidrocefalia , Inyecciones Intravenosas , Inyecciones Subcutáneas , Masculino , Tumores Neuroectodérmicos Primitivos/tratamiento farmacológico , Tiotepa/líquido cefalorraquídeo , Tiotepa/farmacocinéticaRESUMEN
A Phase I trial of thiotepa (TT) administered as an i.v. bolus was performed in 19 children with refractory malignancies. The starting dose was 25 mg/m2 with escalations to 50, 65, and 75 mg/m2. Seven additional patients were treated with 8-h infusions at 50 or 65 mg/m2. The maximum tolerated bolus dose was 65 mg/m2. Reversible myelosuppression was the dose-limiting toxicity. The plasma and cerebrospinal fluid (CSF) pharmacokinetic parameters of TT and its major active metabolite tepa (TP) were also evaluated. When the bolus or infusion methods of TT administration were compared, there was little difference observed in any pharmacokinetic parameter for either TT or TP. The plasma disappearance of TT was rapid and biphasic with half-lives of 0.14 to 0.32 and 1.34 to 2.0 h. Dose-dependent pharmacokinetics was demonstrated by steadily declining plasma clearance with increasing TT dose. Clearance values declined from 28.6 liters/m2/h at the 25-mg/m2 dose to 11.9 liters/m2/h at the 75-mg/m2 dose. The half-life of TP was longer than that of TT and ranged between 4.3 and 5.6 h. There was evidence of the saturation of TP production. TT and TP both exhibited excellent penetration into the CSF, producing lumbar and ventricular concentrations which were nearly identical to simultaneous plasma concentrations. In one patient with a Rickham reservoir, the CSF:plasma area under the (concentration x time) curve ratios for TT and TP were 1.01 and 0.95, respectively. The above data indicate that TT can be safely administered to pediatric patients at doses higher than conventionally used. The favorable CSF penetration of TT and TP suggests that Phase II studies of TT be considered in patients with central nervous system tumors.